Search research articles
Contact Us
Filters
Showing results (51-60 of 132) with videos related to
Page
of 14
Sort By:
Journal of Molecular Neuroscience : MN
|
May 19, 2015
Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease
Michael J Hurley, Pascal F Durrenberger, Steve M Gentleman, et al.
Journal of Neuroinflammation
|
June 7, 2005
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Emilie Croisier, Linda B Moran, David T Dexter, et al.
Annals of Neurology
|
September 1, 1994
Glutathione-related enzymes in brain in Parkinson's disease
J Sian, D T Dexter, A J Lees, et al.
Neuroreport
|
January 25, 2003
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle
Krishna P Datla, Hilary E Murray, Arani V Pillai, et al.
Journal of Neurochemistry
|
June 25, 2009
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease
Lilia Marinova-Mutafchieva, Mona Sadeghian, Lauren Broom, et al.
Free Radical Research
|
November 22, 2005
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease
Virginia Zbarsky, Krishna P Datla, Shabnam Parkar, et al.
Leukemia
|
November 11, 1999
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy
N Chinnasamy, J Rafferty, L Lashford, et al.
The European Journal of Neuroscience
|
October 4, 2005
Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease
A C Vernon, S Palmer, K P Datla, et al.
Free Radical Biology & Medicine
|
December 28, 2010
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease
Lauren Broom, Lilia Marinova-Mutafchieva, Mona Sadeghian, et al.
Free Radical Research
|
February 1, 1996
Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease
J P Spencer, A Jenner, J Butler, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 132) with videos related to
Sort By:
Page
of 14
Journal of Molecular Neuroscience : MN
|
May 19, 2015
Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease
Michael J Hurley, Pascal F Durrenberger, Steve M Gentleman, et al.
Journal of Neuroinflammation
|
June 7, 2005
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Emilie Croisier, Linda B Moran, David T Dexter, et al.
Annals of Neurology
|
September 1, 1994
Glutathione-related enzymes in brain in Parkinson's disease
J Sian, D T Dexter, A J Lees, et al.
Neuroreport
|
January 25, 2003
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle
Krishna P Datla, Hilary E Murray, Arani V Pillai, et al.
Journal of Neurochemistry
|
June 25, 2009
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease
Lilia Marinova-Mutafchieva, Mona Sadeghian, Lauren Broom, et al.
Free Radical Research
|
November 22, 2005
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease
Virginia Zbarsky, Krishna P Datla, Shabnam Parkar, et al.
Leukemia
|
November 11, 1999
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy
N Chinnasamy, J Rafferty, L Lashford, et al.
The European Journal of Neuroscience
|
October 4, 2005
Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease
A C Vernon, S Palmer, K P Datla, et al.
Free Radical Biology & Medicine
|
December 28, 2010
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease
Lauren Broom, Lilia Marinova-Mutafchieva, Mona Sadeghian, et al.
Free Radical Research
|
February 1, 1996
Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease
J P Spencer, A Jenner, J Butler, et al.
Page
of 14